Literature DB >> 21227915

Pathogenesis of progressive multifocal leukoencephalopathy--revisited.

Martyn K White1, Kamel Khalili.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system that is rare even though the proven etiological agent of PML, the polyomavirus JC (JC virus), is ubiquitous within the human population. The common feature of PML cases appears to be underlying immunosuppression, and PML has gained clinical visibility because of its association with human immunodeficiency virus and AIDS and its occurrence as a side effect of certain immunomodulatory drugs. A hypothesis has gained general acceptance that JC virus causes a primary infection in childhood and enters a latent state, after which immunosuppression allows viral reactivation leading to PML. Nonetheless, many important aspects of PML pathogenesis remain unclear, including the molecular bases of latency and reactivation, the site(s) of latency, the relationship of archetype and prototype virus and the mode of virus transmission within the body and between individuals. In this review, we will revisit these areas and examine what the available evidence suggests.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21227915      PMCID: PMC3072716          DOI: 10.1093/infdis/jiq097

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  69 in total

1.  Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy.

Authors:  B L Padgett; D L Walker; G M ZuRhein; R J Eckroade; B H Dessel
Journal:  Lancet       Date:  1971-06-19       Impact factor: 79.321

2.  Polyoma-like virions in a human demyelinating disease.

Authors:  G M Zu Rhein
Journal:  Acta Neuropathol       Date:  1967-03-06       Impact factor: 17.088

3.  Progressive multifocal leukoencephalopathy.

Authors:  B R Brooks; D L Walker
Journal:  Neurol Clin       Date:  1984-05       Impact factor: 3.806

4.  The epidemiology of human polyomaviruses.

Authors:  D L Walker; B L Padgett
Journal:  Prog Clin Biol Res       Date:  1983

5.  Release of simian virus 40 virions from epithelial cells is polarized and occurs without cell lysis.

Authors:  E T Clayson; L V Brando; R W Compans
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

6.  Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals.

Authors:  Y Yogo; T Kitamura; C Sugimoto; T Ueki; Y Aso; K Hara; F Taguchi
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

7.  Trans-activation of the JC virus late promoter by the tat protein of type 1 human immunodeficiency virus in glial cells.

Authors:  H Tada; J Rappaport; M Lashgari; S Amini; F Wong-Staal; K Khalili
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

8.  Direct isolation and characterization of JC virus from urine samples of renal and bone marrow transplant patients.

Authors:  C Myers; R J Frisque; R R Arthur
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

9.  Human polyomavirus JC virus genome.

Authors:  R J Frisque; G L Bream; M T Cannella
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

10.  Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera.

Authors:  F Taguchi; J Kajioka; T Miyamura
Journal:  Microbiol Immunol       Date:  1982       Impact factor: 1.955

View more
  70 in total

Review 1.  Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?

Authors:  Tim Raine
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

Review 2.  Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

Authors:  Eleonora Tavazzi; Martyn K White; Kamel Khalili
Journal:  Rev Med Virol       Date:  2011-09-21       Impact factor: 6.989

Review 3.  Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies.

Authors:  A Bellizzi; C Nardis; E Anzivino; D M Rodìo; D Fioriti; M Mischitelli; F Chiarini; V Pietropaolo
Journal:  J Neurovirol       Date:  2012-02       Impact factor: 2.643

Review 4.  Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathy.

Authors:  Martyn K White; Ilker K Sariyer; Jennifer Gordon; Serena Delbue; Valeria Pietropaolo; Joseph R Berger; Kamel Khalili
Journal:  Rev Med Virol       Date:  2015-12-14       Impact factor: 6.989

5.  Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab.

Authors:  Simone Giannecchini; Valeria Clausi; Alessandra Vultaggio; Lisa Macera; Fabrizio Maggi; Francesco Martelli; Alberta Azzi; Enrico Maggi; Andrea Matucci
Journal:  J Neurovirol       Date:  2012-01-27       Impact factor: 2.643

Review 6.  Animal Models for Progressive Multifocal Leukoencephalopathy.

Authors:  Martyn K White; Jennifer Gordon; Joseph R Berger; Kamel Khalili
Journal:  J Cell Physiol       Date:  2015-12       Impact factor: 6.384

7.  No reactivation of JCV and CMV infections in the temporal cortex and cerebellum of sporadic Creutzfeldt-Jakob disease patients.

Authors:  Judith Löffler; Susanne Krasemann; Inga Zerr; Jakob Matschke; Markus Glatzel
Journal:  Am J Neurodegener Dis       Date:  2014-12-05

Review 8.  Update on progressive multifocal leukoencephalopathy.

Authors:  Israel Steiner; Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2012-12       Impact factor: 5.081

9.  Specific and quantitative detection of Human polyomaviruses BKPyV and JCPyV in the healthy Pakistani population.

Authors:  Iqra Hussain; Fareeda Tasneem; Muhammed Umer; Ayesha Pervaiz; Muslim Raza; Muhammad Imran Arshad; Naveed Shahzad
Journal:  Virol J       Date:  2017-04-24       Impact factor: 4.099

Review 10.  Neurobehavioral Manifestations of Human Immunodeficiency Virus/AIDS: Diagnosis and Treatment.

Authors:  Elyse J Singer; April D Thames
Journal:  Neurol Clin       Date:  2016-02       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.